- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00639379
Comparison of Two Toric Contact Lenses on Current Toric Wearers
A Multi-Center, Subject Masked, Randomized, Two Week Crossover Design, Investigation of the Acuvue Cypress Toric Silicone Hydrogel Lens Compared to the Bausch & Lomb SofLens66® Toric Hydrophilic Lens
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Up to 7 sites in the US will participate. Each investigator will have both test and control lens types. There will be a maximum of 6 scheduled visits:
Visit 1: Habitual lens evaluation / Baseline / Trial fitting Visit 2: Dispensing (to be combined with Visit 1 where possible), Visit 3: Questionnaire only (no exam) 7 days (±2) after dispensing, Visit 4: 2 week follow-up 14 days (±3) after dispensing, and dispense second lens type, Visit 5: Questionnaire only (no exam) 7 days (±2) after 2nd lens dispense, Visit 6: 2 week follow-up 14 days (±3) after 2nd lens dispense
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Ted Brink and Associates
-
Orlando, Florida, United States, 32801
- Eola Eyes
-
-
Georgia
-
Morrow, Georgia, United States, 30260
- Clayton Eye Center
-
-
Missouri
-
St Louis, Missouri, United States, 63144
- The Koetting Associates Inc.
-
-
North Carolina
-
Concord, North Carolina, United States, 28025
- Southern Eyes
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Western Reserve Vision Care
-
-
Tennessee
-
Brentwood, Tennessee, United States, 37027
- Primary Eyecare Group, P.C.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be at least 18 and less than or equal to 45 years of age, have a need for vision correction and wear contact lenses in BOTH eyes (monovision or uni-ocular fitting is NOT allowed).
- Be able to read J1 at near WITHOUT the aid of a near addition over the distance prescription.
- Be a currently successful wearer for at least 3 months of B&L SofLens 66 Toric hydrogel lenses.
- Be able and willing to adhere to the instructions set forth in the protocol.
- Agree to wear their contact lenses in both eyes on a daily wear schedule for at least 8 hours per day every day during the study.
- Have a distance spectacle spherical component between -1.00 D and -5.25 D with cylinder in the range of 0.75 D to 2.25 D and cylinder axis within 10 ° of the vertical and within 30° of the horizontal in both eyes (when the subject's prescription is presented in minus cylinder form).
- Have a best corrected manifest refraction visual acuity of at least 20/25 or better in each eye.
- Be in good general health, based on his/her knowledge.
- Must be given an explanation of the study objectives, lens and solutions usage requirements and visit schedule. The subject must read, indicate understanding of and agree to begin participation in the clinical study. The subject must then sign the Informed Consent Form in the presence of the Investigator or their designee.
Exclusion Criteria:
- Presbyopic or has the need for a near add for reading.
- Previous refractive surgery; current or previous orthokeratology treatment.
- Aphakia, keratoconus or a highly irregular cornea.
- The presence of ocular or systemic disease or has the need for medication (ocular or systemic) which might interfere with contact lens wear or which would cause the lenses to be removed more than twice a day. (e.g., Sjögren's syndrome, type II diabetes, allergies).
- A known history of corneal hypoesthesia (reduced corneal sensitivity.)
- Anterior uveitis or iritis (past or present).
- A history of recurrent erosions, corneal infiltrates corneal ulcer or fungal infections.
- Clinically significant (grade 3 or 4) anterior segment abnormalities; inflammations or infections of the eye, eyelids, or associated structures.
Slit lamp findings that would contraindicate contact lens wear such as:
- Pathological dry eye or associated findings
- Pterygium or corneal scars within the visual axis
- Neovascularization >1mm in from the limbus
- History of giant papillary conjunctivitis (GPC) worse than Grade 2
- Meibomian gland dysfunction, blepharitis, or seborrhoeic dermatitis
- Current pregnancy or lactation (to the best of the subject's knowledge).
- Actively participating in another clinical study at any time during this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: senofilcon A
senofilcon A toric daily wear contact lenses
|
silicone hydrogel toric lens, 2 wk replacement, daily wear
Other Names:
|
|
Active Comparator: alphafilcon A
alphafilcon A toric daily wear contact lenses
|
hydrogel toric lens, 2 wk replacement, daily wear
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lens Orientation Within 5 Degrees
Time Frame: 1 minute after insertion
|
Number of eyes with lens orientation within 5 degrees of optimal orientation within 1 minute of contact lens insertion.
|
1 minute after insertion
|
|
Lens Stability
Time Frame: 10-15 minutes after insertion
|
Number of eyes with the amount of rotation induced from a blink within 5 degrees of settled orientation.
|
10-15 minutes after insertion
|
|
Subjective Lens Comfort
Time Frame: 1 and 2 weeks
|
A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1=most negative response to 5=most positive response, was used to derive comfort outcomes.
The analysis shows the difference in outcome between the test and control.
>0=comfortable, <0=uncomfortable.
|
1 and 2 weeks
|
|
Subjective Vision
Time Frame: 1 and 2 weeks
|
A weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1=most negative response to 5=most positive response, was used to derive vision outcomes.
The analysis shows the difference in outcome between the test and control.
>0=satisfactory vision, <0=unsatisfactory vision.
|
1 and 2 weeks
|
|
Overall Corneal Staining
Time Frame: after 2 weeks use
|
Corneal staining measured using the National Eye Institute grading scale of grade 0 = normal, grade 1 = mild, grade 2 = moderate, grade 3 = severe.
|
after 2 weeks use
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-0802
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ametropia
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
European Vision Institute Clinical Research NetworkCompletedNormal Subjects, AmetropiaSpain
-
Alcon ResearchCompletedMyopia | Hyperopia | Refractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
Unicon Optical Co. Ltd.Recruiting
Clinical Trials on senofilcon A toric
-
Johnson & Johnson Vision Care, Inc.Foresight Regulatory Strategies, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.CompletedAstigmatismUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed
-
Johnson & Johnson Vision Care, Inc.Foresight Regulatory Strategies, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedAstigmatismAustralia, United States
-
Johnson & Johnson Vision Care, Inc.Completed
-
CooperVision, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedAstigmatismUnited Kingdom